GlassScriptPhysician profile
Alireza Eghtedar
NPI 1811280431
$96,151.24
in general payments reported to CMS, 2019-2025
34 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91K · 2020: $3,095 · 2021: $164 · 2022: $157 · 2023: $389 · 2024: $394 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $57,036.61 | 2019 | |
| Celgene Corporation | $15,140.84 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $11,657.31 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $7,208.85 | 2019-2020 | |
| Verastem, INC. | $2,765.00 | 2019 | |
| Abbvie INC. | $385.69 | 2023-2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $311.81 | 2019-2023 | Imbruvica |
| Janssen Biotech, INC. | $239.99 | 2019-2022 | |
| Pfizer INC. | $180.82 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $170.01 | 2019-2024 | Reblozyl |
| Astellas Pharma US INC | $107.19 | 2024-2025 | Xospata |
| Incyte Corporation | $89.57 | 2019-2025 | Jakafi |
| Genentech USA, INC. | $81.22 | 2020-2023 | Polivy, Columvi, Lunsumio |
| Sumitomo Pharma America, INC. | $73.16 | 2025 | |
| Blueprint Medicines Corporation | $72.11 | 2024-2025 | Ayvakit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $65.70 | 2020 | |
| Merck Sharp & Dohme LLC | $65.33 | 2019-2023 | Prevymis, Dificid |
| Rigel Pharmaceuticals, INC. | $62.63 | 2019 | |
| Daiichi Sankyo INC. | $54.46 | 2024-2025 | Vanflyta |
| Beigene USA, INC. | $51.91 | 2020-2023 | Brukinsa |
| Kite Pharma, INC. | $49.28 | 2019 | |
| Genmab U.S., INC. | $48.65 | 2023-2024 | Epkinly |
| Glaxosmithkline, LLC. | $37.78 | 2024-2025 | Ojjaara |
| Agios Pharmaceuticals, INC. | $33.06 | 2019 | |
| Genzyme Corporation | $24.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.29 | 2025 | |
| Seagen INC. | $22.90 | 2023 | Adcetris |
| Invivyd INC | $22.69 | 2025 | Pemgarda |
| Regeneron Healthcare Solutions, INC. | $22.61 | 2025 | Lynozyfic |
| Akcea Therapeutics, INC. | $18.26 | 2019 | |
| Stemline Therapeutics INC. | $14.51 | 2025 | Elzonris |
| Adaptive Biotechnologies Corporation | $14.00 | 2023 | Clonoseq |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alireza Eghtedar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.